2007
DOI: 10.1590/s0066-782x2007000400004
|View full text |Cite
|
Sign up to set email alerts
|

Estudo comparativo randomizado do implante de Stent de aço inoxidável recoberto por carbono semelhante ao diamante versus não recoberto em pacientes com doença arterial coronariana

Abstract: SummaryObjective: To compare restenosis and major cardiac event rates at one and six months after DLC-coated stent implantation with those of uncoated stents. Méthods

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
6
0

Year Published

2008
2008
2022
2022

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 13 publications
(6 citation statements)
references
References 27 publications
0
6
0
Order By: Relevance
“…However, the initial clinical results seem promising, and long term studies should provide the safety and efficacy data needed. 136 To reduce in-stent restenosis, new trends combine a thromboresistant stent coating with a drug release system. Stents coated with drugs (sirolimus, paclitaxel, actinomycin D, tacrolimus, estradiol, dexamethasone) acting as inhibitors of the cell migration and cell cycle progression with antiproliferative and anti-inflammatory activities are under evaluation in many clinical trails.…”
Section: Discussionmentioning
confidence: 99%
“…However, the initial clinical results seem promising, and long term studies should provide the safety and efficacy data needed. 136 To reduce in-stent restenosis, new trends combine a thromboresistant stent coating with a drug release system. Stents coated with drugs (sirolimus, paclitaxel, actinomycin D, tacrolimus, estradiol, dexamethasone) acting as inhibitors of the cell migration and cell cycle progression with antiproliferative and anti-inflammatory activities are under evaluation in many clinical trails.…”
Section: Discussionmentioning
confidence: 99%
“…Earlier efforts focused on therapeutic effects such as reduced restenosis, using 1) inorganic coatings, including diamond-like carbon (Airoldi et al, 2004), pyrolytic carbon (Danzi et al, 2004), titanium nitride oxide (Windecker et al, 2005), and carbide (Unverdorben et al, 2003); 2) gene-eluting coatings, incorporating mRNA, siRNA, miRNA, or plasmid DNA of therapeutic genes in the coating; (Feldman et al, 2000;Sharif et al, 2012;Wang et al, 2021) 3) cell-seeded stent, using endothelial cells or progenitor cells (Zhu et al, 2008;Shi et al, 2010;Jantzen et al, 2011;Raina et al, 2014). The inorganic coatings provided ineffective or inconclusive performance (e.g., restenosis rate), compared to uncoated BMS (Kim et al, 2005;Meireles et al, 2007;O'Brien and Carroll, 2009). The gene-eluting coatings, like DES, incorporate genes for therapeutic moiety, but offer a longer term efficacy and a wider variety of therapeutic strategies beyond suppressing cell proliferation for restenosis inhibition (Yang et al, 2013;Adeel and Sharif, 2016;Fishbein et al, 2017;Hytönen et al, 2018).…”
Section: Regenerative Stent Surfacementioning
confidence: 99%
“…[152] Similarly, the Diamond Flex AS and Phytis stents (Phytis Medical Devices GmbH, Berlin, Germany) compared against bare SS and Multi-Link Penta SS, respectively, showed no significant differences in angiographic restenosis rates. [11,153,154] Titanium-nitride-oxide (TiNOX) coatings have also been developed with the hope that nitrogen in the oxide layer will be a source to facilitate the evolution of nitric oxide (NO), which is known to support endothelial function and improve vasodilation. [11] Several clinical studies have shown that these titanium-nitride-oxide stents reduce restenosis and MACE, [155,156] even when compared against DES.…”
Section: Permanent Metallicsmentioning
confidence: 99%